Dyslipidaemia pattern and prevalence among type 2 diabetes mellitus patients on lipid-lowering therapy at a tertiary hospital in central South Africa

Pitso, L; Mofokeng, Thabiso; Nel, Riëtte

doi:10.1186/s12902-021-00813-7

Cited by 16 publications

(18 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[40] However, the prevalence of dyslipidemia in this study is lower than what was reported from South Africa (86.7%), another developing sub-Saharan African nation. [41] In contrast to this, based on a study done in Ghana, which is also a developing sub-Saharan African country, the prevalence of dyslipidemia in T2D was lower compared to what was found in this meta-analysis (53% vs. 63%). [42] These differences might be due to the differences in the sociodemographic characteristics of the populations involved in the various studies.…”

Section: Discussioncontrasting

confidence: 93%

Lipid profiles of Nigerians living with type 2 diabetes mellitus: A systematic review and meta-analysis

Azeez¹,

Adio

Bamidele

2021

Journal of Diabetes and Endocrine Practice

View full text Add to dashboard Cite

Introduction: Dyslipidemia is often associated with type 2 diabetes (T2D), with both having an additive effect on cardiovascular risk. The objective of the meta-analysis was to determine the prevalence of dyslipidemia in individuals living with T2D mellitus in Nigerian and to examine the pattern of their dyslipidemia. Methods: The study followed the preferred reporting items for systematic reviews and meta-analyses guidelines. Medical databases such as PubMed, Google Scholar, African Journals Online, and SCOPUS as well as the gray literature were systematically searched. MetaXL was used for statistical analysis adopting the random effect model. Heterogeneity was determined using the I2 statistic, while publication bias was assessed with the funnel plot. Results: Twenty-two studies met the eligibility criteria for the meta-analysis. The total sample size was 3575. The prevalence of dyslipidemia among Nigerians living with diabetes ranges from 25% to 97.1%. The pooled prevalence of dyslipidemia among Nigerians living with T2D was 63% (95% confidence interval [CI]: 52%–72%). I2 statistic was 97%. The funnel plot implied minimal publication bias. The pooled prevalence of elevated low-density lipoprotein cholesterol was 33% (95% CI: 18%–49%). The pooled prevalence of elevated hypertriglyceridemia was 88% (95% CI: 84%–91%). The pooled prevalence of low high-density lipoprotein cholesterol (HDL-C) was 47% (95% CI: 32%–62%). The pooled prevalence of elevated hypercholesterolemia was 33% (95% CI: 23%–43%). Conclusions: The prevalence of dyslipidemia among Nigerians with T2D mellitus is very high. The most common abnormalities are hypertriglyceridemia and low HDL-C.

show abstract

Section: Discussioncontrasting

confidence: 93%

Lipid profiles of Nigerians living with type 2 diabetes mellitus: A systematic review and meta-analysis

Azeez¹,

Adio

Bamidele

2021

Journal of Diabetes and Endocrine Practice

View full text Add to dashboard Cite

show abstract

“…A reduction of LDL-C levels by 38.7 mg/dL (1 mmol/L) reduces the 5-year incidence of CVD by 23% [24,25], and optimal clinical benefits can be seen up to an LDL-C level of 40 mg/dl [26]. Despite the benefits of effective management, dyslipidaemia is often unscreened and undertreated across many regions of the world, including sub-Saharan Africa [27][28][29][30]. Malawi lacks data on the screening and management of dyslipidaemia among patients with DM and hypertension in many health facilities, including tertiary referral hospitals.…”

Section: Introductionmentioning

confidence: 99%

High prevalence of dyslipidaemia among persons with diabetes mellitus and hypertension at a tertiary hospital in Blantyre, Malawi

Katundu

Mukhula

Phiri

et al. 2022

BMC Cardiovasc Disord

View full text Add to dashboard Cite

Background Dyslipidaemia drives the process of atherosclerosis, and hence a significant modifiable risk factor complicating hypertension and diabetes. In Malawi, the prevalence, screening and management of dyslipidaemia among persons with diabetes mellitus have not been reported. This study aimed to investigate the prevalence, biochemical characteristics, screening and management practices for dyslipidaemia among persons with diabetes mellitus, hypertension, and diabetes mellitus and hypertension comorbidity at Queen Elizabeth Central hospital in Blantyre, Malawi. Methods This was a cross-sectional study conducted in 2021. A total of 256 adult participants (diabetes mellitus = 100); hypertension = 100; both conditions = 56) were included. Medical data and anthropometric measurements were recorded. Blood samples were analysed for HbA1C and serum lipids. Associated risk factors for dyslipidaemia were also assessed. Results Dyslipidaemia was prevalent in 58%, 55%, and 70% of participants with diabetes mellitus, hypertension, and both conditions. Low-density lipoprotein cholesterol (LDL-C) dyslipidaemia was the most common in all participant groups. Participants with both diabetes and hypertension had 2.4 times (95% CI 1.2–4.6) increased risk of LDL-C dyslipidaemia than those with diabetes alone (p < 0.02). Being overweight or obese and age over 30 years were risk factors for dyslipidaemia in participants with diabetes mellitus alone (OR 1.3 (95% CI 1.1–1.6), p < 0.04, and OR 2.2 (95% CI 1.2–4.7) (p < 0.01), respectively. Overweight and obesity predicted LDL-C dyslipidaemia in hypertensive patients (OR 3.5 (95% CI 1.2–9.9) p < 0.001). Poorly controlled hypertension and the use of beta-blockers and thiazide diuretics predicted dyslipidaemia among patients with both diabetes mellitus and hypertension (OR 6.50 CI 1.45–29.19; and OR 5.20 CI 1.16–23.36 respectively). None of the participants had a lipogram performed before the study or were on lipid-lowering therapy. Conclusions Dyslipidaemia with LDL-C derangement was highly prevalent, especially in individuals with both diabetes mellitus and hypertension, and there was absent use of lipid-lowering therapy. Screening and managing dyslipidaemia should be reinforced to reduce the risk of cardiovascular complications in this population at increased risk.

show abstract

“…Dyslipidaemia also serves an important role in the progression of vascular complications caused by diabetes. A recent study indicated a high prevalence of dyslipidaemia among patients with diabetes ( 38 ). Sex, advancing age, long duration of diabetes, increased body-mass index (BMI) and high blood pressure were risk factors associated with the prevalence of dyslipidaemia ( 39 ).…”

Section: Discussionmentioning

confidence: 99%

Risk assessment of amputation in patients with diabetic foot

Tănăsescu

Sabău²,

Moisin³

et al. 2022

Exp Ther Med

View full text Add to dashboard Cite

The prevalence of diabetes has increased dramatically over the past decade, especially in developing countries, reaching pandemic proportions. Although has been the most important factor influencing the prevalence of type 2 diabetes, the prevalence of type 2 diabetes is on the increase among younger adults. The subsequent rate of increase with age is variable, which is more evident in societies where the general prevalence of the disease is higher. Based on clinical and statistical data obtained from the patients who were admitted to The First and Second Surgery Wards in the Sibiu County Emergency University Clinical Hospital (Sibiu, Romania) and the Proctoven Clinic (Sibiu, Romania) between January 2018 and December 2020, the present study attempted to devise a risk score that can be applied for the benefit of patients. The ultimate aim was that this risk score may be eventually applied by diabetologists and surgeons to assess the risk of amputation in patients with diabetic foot lesions. An important part in the therapeutic management of diabetic foot injuries is the assessment of risk factors. Using this risk score system devised, the risk factors that were found to exert influence in aggravating diabetic foot injuries are smoking, obesity, dyslipidaemia, unbalanced diabetes mellitus (glycated haemoglobin ≥7.5%), duration of diabetes >5 years, hepatic steatosis and the co-existence of various heart diseases. To conclude, all these risk factors aforementioned can decrease the effectiveness of treatment and can have a significant impact on the quality of life, if they are not well known.

show abstract

Dyslipidaemia pattern and prevalence among type 2 diabetes mellitus patients on lipid-lowering therapy at a tertiary hospital in central South Africa

Cited by 16 publications

References 27 publications

Lipid profiles of Nigerians living with type 2 diabetes mellitus: A systematic review and meta-analysis

Lipid profiles of Nigerians living with type 2 diabetes mellitus: A systematic review and meta-analysis

High prevalence of dyslipidaemia among persons with diabetes mellitus and hypertension at a tertiary hospital in Blantyre, Malawi

Risk assessment of amputation in patients with diabetic foot

Contact Info

Product

Resources

About